Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Nov 15;108(10):3302-4.
doi: 10.1182/blood-2006-04-016709. Epub 2006 Aug 8.

Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia

Sima Jeha  1 , Frederick Behm, Deqing Pei, John T Sandlund, Raul C Ribeiro, Bassem I Razzouk, Jeffrey E Rubnitz, Nobuko Hijiya, Scott C Howard, Cheng Cheng, Ching-Hon Pui
Affiliations

Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia

Sima Jeha et al. Blood. .

Abstract

CD20 expression is associated with inferior survival in adults with acute lymphoblastic leukemia (ALL). We analyzed the prognostic impact of CD20 expression in 353 children with B-cell precursor ALL treated in 3 consecutive St Jude Total Therapy studies. CD20 expression (> 20%) was found in 169 patients (48%) and was more frequent in patients between 1 and 10 years of age than in those younger than 1 or older than 10 years (P = .001). None of 14 patients with MLL-AF4 expressed CD20. There was no association between CD20 expression and E2A-PBX, TEL-AML1, ploidy, white blood cell count at diagnosis, or sex. In contrast to the experience in adult ALL, our patients with CD20 expression tended to have a better treatment outcome than those without the expression: 5-year event-free survival 84% +/- 2.9% versus 78% +/- 3.1% (P = .08). These data suggest that CD20 expression is not associated with inferior outcome in pediatric patients treated with contemporary regimens.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Event-free survival and risk of relapse according to CD20 expression.
See this image and copyright information in PMC

References

    1. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103: 4396-4407. - PubMed
    1. Thomas DA, Cortes J, Faderl S, et al. Outcome with the hyper-CVAD and rituximab regimen in Burkitt's (BL) and Burkitt's-like (BLL) leukemia/lymphoma (abstract). Blood. 2004;104: 901a. - PubMed
    1. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14: 520-535. - PubMed
    1. Thomas DA, Cortes J, Giles F, et al. The modified hyper-CVAD regimen in newly diagnosed adult acute lymphoblastic leukemia (ALL) (abstract). Blood. 2001;98: 590a.
    1. Thomas DA, Cortes J, Giles F, et al. Update of the modified hyper-CVAD regimen in newly diagnosed adult acute lymphocytic leukemia (ALL) (abstract). Blood. 2003;102: 880a.

Publication types